Developer docs
API playgroundTry for free, no card

Search company profiles

OXILIO LIMITED

Full company profile

uuid028qlcd

Namestring
OXILIO LIMITED
Legal namestring
OXILIO LIMITED
Websiteurl
oxilio.co.uk
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Oxilio Limited is a London-based, privately held pharmaceutical drug development company founded in 2019 that operates a platform-based approach centred on identifying, reformulating, and commercialising off-patent drugs for new oncology indications. Its core services comprise drug repurposing (leveraging existing registration and post-marketing real-world safety data to reduce development risk), novel formulation development (enhancing bioavailability, reducing pill burden, and generating new intellectual property around off-patent molecules), and "Gold Standard Modelling and Simulation" (in-silico optimisation of dose and dosing regimen to inform clinical trial design and regulatory decision-making). The company currently lists two drug candidates in its pipeline — OXL001, for which it secured UK MHRA/REC approval in September 2022 and completed a first clinical trial in June 2023, and OXL002, a parallel reformulation candidate — both based on previously approved drugs being re-engineered for cancer therapy.

The business model is presently pre-commercial: Oxilio has no marketed products, pricing is not applicable, and revenue figures are not disclosed. Anticipated income streams include one-time licensing transactions and ongoing royalty arrangements with development and commercialisation partners, alongside licence agreements already established with TRx Biosciences Limited (October 2021) and Nuformix plc (September 2021, with the exclusive option exercised in March 2021). CMC and clinical manufacturing execution is outsourced to contract partners such as Quotient Sciences. IP is being actively consolidated, including the September 2023 acquisition of Nuformix plc patents and the March 2022 acquisition of LSHS Consulting Ltd. for IP and drug development expertise. The company is led by Co-CEOs Ralph Browning (finance and capital markets background at Deutsche Bank, MasterCard International, NatWest, and ICI) and Dr Simon Yaxley (Oxford-trained neuroscientist who previously founded Premier Research and scaled it to 1,400+ drug development professionals across 26 countries), operates with 1–10 employees from its registered office at 86-90 Paul Street, London, and recently incorporated a wholly-owned subsidiary, Biovara Ltd., in April 2025 to house a distinct line of business.

Short descriptiontext

OXILIO LIMITED is a London-based clinical-stage pharmaceutical company that repurposes and reformulates off-patent drugs for oncology indications, advancing candidates OXL001 and OXL002 through outsourced CMC and clinical development toward licensing-based commercialisation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repurposing, oncology drug development, novel drug formulation, pharmaceutical reformulation, cancer therapeutics
Industry1 code
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Drug Development
Social media profiles1 record
Revenue model2 records
1Drug Commercialisation
TypeOne Time License
Description

Revenue generated from bringing repurposed cancer drugs to market through regulatory approval and commercial launch

oxilio.co.uk
2Licensing and Royalty Agreements
TypeLicensing Royalties
Description

Licence agreements with partners such as TRx Biosciences Limited and Nuformix plc generating licensing revenue

oxilio.co.uk
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Oxilio is a clinical-stage pharmaceutical company that identifies, repurposes and reformulates existing approved drugs for new oncology indications. Its pipeline includes two drug candidates, OXL001 and OXL002, both based on off-patent drugs being reformulated for cancer therapy with enhanced bioavailability and reduced pill burden. The company leverages its Gold Standard Modelling and Simulation platform to optimize dosing and formulation in-silico, accelerating clinical development and reducing time, cost and risk relative to de novo drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Significant reduction in development cost compared to de novo drug development
+2 more records
Product overview1 text field

Oxilio is a pharmaceutical drug development company operating a platform-based approach centered on drug repurposing and reformulation for cancer therapy. The company leverages three core services: Drug Repurposing (identifying new uses for existing approved drugs), Reformulation (optimizing bioavailability and dosing through novel formulations), and Gold Standard Modelling and Simulation (computational optimization of dosing regimens). The current drug development pipeline centers on two named drug candidates—OXL001 and OXL002—both based on off-patent drugs being reformulated for enhanced cancer treatment outcomes. This approach enables the company to reduce development risk, cost, and time-to-market by building on existing safety and efficacy data.

Product and service5 records
1OXL001
CategoryDrug candidate (oncology)
Description

Repurposed and reformulated drug candidate based on an off-patent drug previously approved for a different indication; undergoing novel formulation development to enhance performance, reduce production costs and target cancer treatment.

2OXL002
CategoryDrug candidate (oncology)
Description

Reformulation drug candidate based on an off-patent drug previously approved for a different indication; undergoing formulation development to enhance bioavailability, reduce pill burden and improve patient compliance in cancer therapy.

3Drug Repurposing Services
CategoryDrug repurposing service
Description

Identification and development of existing approved drugs for new therapeutic indications in cancer treatment, leveraging substantial existing safety and efficacy data to reduce development cost, time and risk.

4Reformulation Services
CategoryDrug reformulation service
Description

Enhancing drug bioavailability and optimising dose through novel formulation development, aimed at improving patient compliance through reduced pill burden and generating intellectual property opportunities.

5Gold Standard Modelling and Simulation
CategoryPharmaceutical modelling and simulation service
Description

In-silico optimisation of dose and dosing regimen using advanced modelling and simulation techniques to inform clinical trial design and facilitate regulatory decision-making.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1CMS EquIP Programme
Strategic tierMinorTypeOthersAnnounced on2024-04-04
Description

Accepted into CMS EquIP programme in April 2024, providing access to expertise and support services

oxilio.co.uk
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-02-21
Description

OXL001 formulation optimisation and clinical trial preparation contract. Cocrystal formulation optimisation work commissioned. Development partner for clinical manufacturing

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-20
Description

Licence agreement established with TRx Biosciences Limited for development activities related to Oxilio's drug pipeline including clinical evaluation of OXL001 novel formulation

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-13
Description

Licence agreement and exclusive option agreement for drug repurposing technologies. Acquired Nuformix plc patents in September 2023. Exercise of exclusive option agreement in March 2021

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-listed pharmaceutical company specializing in cocrystal and formulation technologies to repurpose existing APIs for new indications. Oxilio's existing licensing partner; uses similar novel-formulation IP approaches on off-patent drugs.

TypeDirect peer
Description

US clinical-stage oncology company using AI-driven drug development and repurposing to advance cancer candidates. Comparable in scale and clinical-stage model, with similar pipeline-of-candidates approach.

TypeEmerging player
Description

US clinical-stage biotech developing repurposed and reformulated oncology candidates with small headcount and clinical-trial-stage assets. Comparable scale and pipeline structure to Oxilio.

TypeOthers
Description

Global CRO focused on oncology, CNS, and pain clinical development — founded by Oxilio co-CEO Dr. Simon Yaxley. Comparable in therapeutic focus and clinical service capability, though Premier is a CRO rather than a sponsor.

TypeBroad incumbent
Description

Clinical-stage oncology company developing small-molecule therapeutics, including candidates with reformulation strategies. Broader oncology biotech with a comparable pipeline-development approach and clinical-stage profile.

6Pharnext
TypeDirect peer
Description

France-based clinical-stage pharma applying drug repurposing to develop combination therapies for neurological and rare diseases. Operates the same 'repurposing-first' development model targeting underserved therapeutic areas.

TypeOthers
Description

UK-based drug development CDMO providing formulation optimization and clinical manufacturing services; existing partner of Oxilio for OXL001. Not a competitor but an adjacent infrastructure provider critical to Oxilio's pipeline.

TypeDirect peer
Description

UK-based clinical-stage pharma focused on developing repurposed and novel small-molecule drugs for oncology and fibrotic disease. Directly comparable as a small-cap oncology drug developer using reformulation/repurposing strategies.

TypeEmerging player
Description

UK-based pharmaceutical developer focused on novel formulations of established drugs; Oxilio's existing clinical evaluation partner for OXL001. Operates in adjacent formulation/repurposing space.

10Biovista Inc.
TypeEmerging player
Description

Drug repurposing company using AI to identify new indications for existing molecules, with oncology and CNS focus. Smaller peer pursuing the same strategy of using computational methods to expand the use of approved drugs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OXILIO LIMITED

Oncology Drug Developmentoxilio.co.uk

OXILIO LIMITED is a London-based clinical-stage pharmaceutical company that repurposes and reformulates off-patent drugs for oncology indications, advancing candidates OXL001 and OXL002 through outsourced CMC and clinical development toward licensing-based commercialisation.

What OXILIO LIMITED does

Oxilio Limited is a London-based, privately held pharmaceutical drug development company founded in 2019 that operates a platform-based approach centred on identifying, reformulating, and commercialising off-patent drugs for new oncology indications. Its core services comprise drug repurposing (leveraging existing registration and post-marketing real-world safety data to reduce development risk), novel formulation development (enhancing bioavailability, reducing pill burden, and generating new intellectual property around off-patent molecules), and "Gold Standard Modelling and Simulation" (in-silico optimisation of dose and dosing regimen to inform clinical trial design and regulatory decision-making). The company currently lists two drug candidates in its pipeline — OXL001, for which it secured UK MHRA/REC approval in September 2022 and completed a first clinical trial in June 2023, and OXL002, a parallel reformulation candidate — both based on previously approved drugs being re-engineered for cancer therapy.

The business model is presently pre-commercial: Oxilio has no marketed products, pricing is not applicable, and revenue figures are not disclosed. Anticipated income streams include one-time licensing transactions and ongoing royalty arrangements with development and commercialisation partners, alongside licence agreements already established with TRx Biosciences Limited (October 2021) and Nuformix plc (September 2021, with the exclusive option exercised in March 2021). CMC and clinical manufacturing execution is outsourced to contract partners such as Quotient Sciences. IP is being actively consolidated, including the September 2023 acquisition of Nuformix plc patents and the March 2022 acquisition of LSHS Consulting Ltd. for IP and drug development expertise. The company is led by Co-CEOs Ralph Browning (finance and capital markets background at Deutsche Bank, MasterCard International, NatWest, and ICI) and Dr Simon Yaxley (Oxford-trained neuroscientist who previously founded Premier Research and scaled it to 1,400+ drug development professionals across 26 countries), operates with 1–10 employees from its registered office at 86-90 Paul Street, London, and recently incorporated a wholly-owned subsidiary, Biovara Ltd., in April 2025 to house a distinct line of business.

OXILIO LIMITED firmographics

Firmographics
Name
OXILIO LIMITED
Legal name
OXILIO LIMITED
Website
https://oxilio.co.uk
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
OXILIO LIMITED is a London-based clinical-stage pharmaceutical company that repurposes and reformulates off-patent drugs for oncology indications, advancing candidates OXL001 and OXL002 through outsourced CMC and clinical development toward licensing-based commercialisation.
Ownership category
akta.pro rank

OXILIO LIMITED industry classification

Industry
Product category
Oncology Drug Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Drug repurposing
  • Oncology drug development
  • Novel drug formulation
  • Pharmaceutical reformulation
  • Cancer therapeutics

Where OXILIO LIMITED is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

OXILIO LIMITED business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Commercialisation: Revenue generated from bringing repurposed cancer drugs to market through regulatory approval and commercial launch
  2. Licensing and Royalty Agreements: Licence agreements with partners such as TRx Biosciences Limited and Nuformix plc generating licensing revenue

Distribution channels1 record

Marketing channels2 records

OXILIO LIMITED product offering

Product offering

Core offering

Oxilio is a clinical-stage pharmaceutical company that identifies, repurposes and reformulates existing approved drugs for new oncology indications. Its pipeline includes two drug candidates, OXL001 and OXL002, both based on off-patent drugs being reformulated for cancer therapy with enhanced bioavailability and reduced pill burden. The company leverages its Gold Standard Modelling and Simulation platform to optimize dosing and formulation in-silico, accelerating clinical development and reducing time, cost and risk relative to de novo drug development.

Product overview

Oxilio is a pharmaceutical drug development company operating a platform-based approach centered on drug repurposing and reformulation for cancer therapy. The company leverages three core services: Drug Repurposing (identifying new uses for existing approved drugs), Reformulation (optimizing bioavailability and dosing through novel formulations), and Gold Standard Modelling and Simulation (computational optimization of dosing regimens). The current drug development pipeline centers on two named drug candidates—OXL001 and OXL002—both based on off-patent drugs being reformulated for enhanced cancer treatment outcomes. This approach enables the company to reduce development risk, cost, and time-to-market by building on existing safety and efficacy data.

Differentiator

Problem solved

Functional benefit

Products and services

  • OXL001 Repurposed and reformulated drug candidate based on an off-patent drug previously approved for a different indication; undergoing novel formulation development to enhance performance, reduce production costs and target cancer treatment.
  • OXL002 Reformulation drug candidate based on an off-patent drug previously approved for a different indication; undergoing formulation development to enhance bioavailability, reduce pill burden and improve patient compliance in cancer therapy.
  • Drug Repurposing Services Identification and development of existing approved drugs for new therapeutic indications in cancer treatment, leveraging substantial existing safety and efficacy data to reduce development cost, time and risk.
  • Reformulation Services Enhancing drug bioavailability and optimising dose through novel formulation development, aimed at improving patient compliance through reduced pill burden and generating intellectual property opportunities.
  • Gold Standard Modelling and Simulation In-silico optimisation of dose and dosing regimen using advanced modelling and simulation techniques to inform clinical trial design and facilitate regulatory decision-making.

Quantifiable outcome

  • Significant reduction in development cost compared to de novo drug development
  • +2 more outcomes

Companies that use OXILIO LIMITED

Customer profile

Segments1 record

Ideal customer profiles2 records

OXILIO LIMITED technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

OXILIO LIMITED partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • CMS EquIP ProgrammeminorOthers · 4 April 2024Accepted into CMS EquIP programme in April 2024, providing access to expertise and support services
  • Quotient SciencescoreImplementation/ SI/ Consulting Partner · 21 February 2022OXL001 formulation optimisation and clinical trial preparation contract. Cocrystal formulation optimisation work commissioned. Development partner for clinical manufacturing
  • TRx Biosciences LimitedcoreStrategic or Co-development Partner · 20 October 2021Licence agreement established with TRx Biosciences Limited for development activities related to Oxilio's drug pipeline including clinical evaluation of OXL001 novel formulation
  • Nuformix plccoreStrategic or Co-development Partner · 13 September 2021Licence agreement and exclusive option agreement for drug repurposing technologies. Acquired Nuformix plc patents in September 2023. Exercise of exclusive option agreement in March 2021

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

OXILIO LIMITED competitors and assessment

Company assessment

Direct peers

  • Nuformix plc: UK-listed pharmaceutical company specializing in cocrystal and formulation technologies to repurpose existing APIs for new indications. Oxilio's existing licensing partner; uses similar novel-formulation IP approaches on off-patent drugs.
  • Lantern Pharma: US clinical-stage oncology company using AI-driven drug development and repurposing to advance cancer candidates. Comparable in scale and clinical-stage model, with similar pipeline-of-candidates approach.
  • Pharnext: France-based clinical-stage pharma applying drug repurposing to develop combination therapies for neurological and rare diseases. Operates the same 'repurposing-first' development model targeting underserved therapeutic areas.
  • Redx Pharma: UK-based clinical-stage pharma focused on developing repurposed and novel small-molecule drugs for oncology and fibrotic disease. Directly comparable as a small-cap oncology drug developer using reformulation/repurposing strategies.

Emerging players

  • Moleculin Biotech: US clinical-stage biotech developing repurposed and reformulated oncology candidates with small headcount and clinical-trial-stage assets. Comparable scale and pipeline structure to Oxilio.
  • TRx Biosciences Limited: UK-based pharmaceutical developer focused on novel formulations of established drugs; Oxilio's existing clinical evaluation partner for OXL001. Operates in adjacent formulation/repurposing space.
  • Biovista Inc. Drug repurposing company using AI to identify new indications for existing molecules, with oncology and CNS focus. Smaller peer pursuing the same strategy of using computational methods to expand the use of approved drugs.

Others

  • Premier Research: Global CRO focused on oncology, CNS, and pain clinical development — founded by Oxilio co-CEO Dr. Simon Yaxley. Comparable in therapeutic focus and clinical service capability, though Premier is a CRO rather than a sponsor.
  • Quotient Sciences: UK-based drug development CDMO providing formulation optimization and clinical manufacturing services; existing partner of Oxilio for OXL001. Not a competitor but an adjacent infrastructure provider critical to Oxilio's pipeline.

Broad incumbents

  • Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapeutics, including candidates with reformulation strategies. Broader oncology biotech with a comparable pipeline-development approach and clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

OXILIO LIMITED social profiles

Digital presence

OXILIO LIMITED financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OXILIO LIMITED leadership team

Management profile

Number of profiles

Profiles2 records

OXILIO LIMITED subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OXILIO LIMITED funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OXILIO LIMITED M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OXILIO LIMITED

What does OXILIO LIMITED do?

Oxilio is a clinical-stage pharmaceutical company that identifies, repurposes and reformulates existing approved drugs for new oncology indications. Its pipeline includes two drug candidates, OXL001 and OXL002, both based on off-patent drugs being reformulated for cancer therapy with enhanced bioavailability and reduced pill burden. The company leverages its Gold Standard Modelling and Simulation platform to optimize dosing and formulation in-silico, accelerating clinical development and reducing time, cost and risk relative to de novo drug development.

Is OXILIO LIMITED a public or private company?

OXILIO LIMITED is a private company. It is classified as venture growth investor backed and is currently operating.

When was OXILIO LIMITED founded?

OXILIO LIMITED was founded in 2019. It employs 1 to 10 people.

Where is OXILIO LIMITED based?

OXILIO LIMITED is headquartered in London, United Kingdom, in the Europe region.

How does OXILIO LIMITED make money?

Two revenue lines are on record. Drug Commercialisation is the primary driver. The others are licensing and Royalty Agreements.

Who are OXILIO LIMITED's main competitors?

Direct peers on record are Nuformix plc, Lantern Pharma, Pharnext and Redx Pharma. Emerging players are Moleculin Biotech, TRx Biosciences Limited and Biovista Inc.. Others are Premier Research and Quotient Sciences. Aprea Therapeutics is listed as a broad incumbent.

Does OXILIO LIMITED have an API?

No public API is recorded for OXILIO LIMITED.

What industry is OXILIO LIMITED in?

OXILIO LIMITED's product category is Oncology Drug Development. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales